Updated

Updated · Gizmodo · Jun 22

Definium Says 100-Microgram LSD Drug Cut Depression Scores by 8.1 Points in Phase III

Updated

Updated · Gizmodo · Jun 22

Definium Says 100-Microgram LSD Drug Cut Depression Scores by 8.1 Points in Phase III

Q: With a 24% remission rate, is this 'miracle' drug a real cure or just a marginal improvement?

It is not a cure, but it is more than a marginal improvement. The key number is not just the 24% remission rate by Week 6, but the gap versus placebo: 24% for DT120 against 3% for placebo in a randomized Phase 3 trial. That 21-point difference is large for depression research, especially after a single dose. The drug also produced an 8.1-point placebo-adjusted improvement on the MADRS depression scale at six weeks, with effects appearing as early as Week 1 and largely holding through Week 12. That said, “miracle” is too strong. A 24% remission rate still means most patients did not reach remission by six weeks. Major depressive disorder is a chronic, relapsing illness, and remission in one trial is not the same as a permanent cure. Longer follow-up, replication, and real-world data will matter. What makes the result notable is the context. Many standard antidepressants are slower, and patients who have already failed conventional treatment often have low odds of remission. Analysts and investigators are calling DT120 potentially “best-in-class” because of the speed, durability and safety profile seen so far, not because it cures everyone. The fairest reading is that DT120 looks like a clinically meaningful advance, particularly for hard-to-treat patients, but not a definitive cure. The excitement is justified by the size and speed of the benefit, while the limits are clear in the remission rate itself.

2 articles · Updated · Gizmodo · Jun 22

149 patients in Definium’s Phase III Emerge trial saw a significantly bigger symptom drop after a single 100-microgram dose of DT120 than with placebo, with an 8.1-point advantage on a standard depression scale at week 6.
35% of DT120 patients achieved at least a 50% symptom reduction versus 7% on placebo, while 12% reached remission versus 3%; benefits eased somewhat but remained visible through 12 weeks.
Definium said it will seek FDA breakthrough therapy designation for the LSD-based treatment, though the data still must be reviewed externally and regulators typically want two positive pivotal trials.
A second Phase III study, Ascend, is still pending, and the company also expects late-stage results for DT120 in generalized anxiety disorder later this year.